Skip to main content

Table 1 Clinical characteristics of the two groups

From: Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Characteristics

No. of patients (%)

P

Total

(n = 118)

NPF group

(n = 58)

DPF group

(n = 60)

Median age (range)

44(22–68)

43(22–65)

45(22–68)

0.214

Gender

 Males

98(83.1)

47(81.0)

51(85.0)

0.371

 Females

20(16.9)

11(19.0)

9(15.0)

 

Clinical stage (China, 2008)

 III

66(55.9)

34(58.6)

32(53.3)

0.347

 IVa

52(44.1)

24(41.4)

28(46.7)

 

T stage

   

0.436

 T1

6(5.1)

3(5.1)

3(5.0)

 

 T2

20(16.9)

12(20.7)

8(13.3)

 

 T3

57(48.3)

27(46.6)

30(50.0)

 

 T4

35(29.7)

16(27.6)

19(31.7)

 

N stage

   

0.585

 N0

3(25.4)

2(3.4)

1(1.6)

 

 N1

27(22.9)

15(25.9)

12(20.0)

 

 N2

67(56.9)

30(51.7)

37(61.7)

 

 N3

21(17.8)

11(19.0)

10(16.7)

Â